Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

September 5, 2019

Primary Completion Date

May 19, 2023

Study Completion Date

September 30, 2025

Conditions
Colorectal CancerADCC
Interventions
DRUG

Folfiri/Cetuximab

"Cetuximab 400 mg/mq intravenously (iv) with load dose of 400 mg/mq at the first cycle followed by 250 mg/mq iv weekly by iv infusion in 90 minutes. The administration of irinotecan will precede that of cetuximab and will consist on a dose of 180 mg/mq iv in 60 minutes every two weeks and it will be followed by fluorouracil (5-FU) at a dose of 400 mg/mq in slow iv bolus at half of lederfolin 200 mg/mq 2-hours infusion. At the end of the infusion of lederfolin an elastomeric pump loaded with 5-FU 2400 mg/mq in continuous 46 hours iv infusion will be applied. Only at the first administration of CT (load dose of cetuximab), irinotecan will not be administered."

Trial Locations (1)

Unknown

RECRUITING

Istituto Nazionale dei Tumori,, Napoli

All Listed Sponsors
lead

National Cancer Institute, Naples

OTHER

NCT03874026 - Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients | Biotech Hunter | Biotech Hunter